SCHEMBL3408431

SCHEMBL3408431

CSCCN1CCC(NC(=O)Nc2ccc3nc(N[C@@H]4CCc5ccccc54)ccc3c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 5/20 0.47
EPHX2 P34913 1/20 0.42
CYP2D6 P10635 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM4E B2RXH2 3/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
LMNA P02545 1/20 0.38
HSD17B10 Q99714 1/20 0.38
DCUN1D1 Q96GG9 1/20 0.38
NPC1 O15118 1/20 0.38
NPY1R P25929 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3414458 0.91 CXCR3 (0.49) CXCR3EPHX2CYP2D6SMN1; SMN2NPSR1
SCHEMBL3408501 0.90 CXCR3 (0.49) CXCR3EPHX2CYP2D6SMN1; SMN2NPSR1
SCHEMBL3408455 0.90 EPHX2 (0.46) CXCR3EPHX2CYP2D6MEN1KMT2A
SCHEMBL3408559 0.89 CXCR3 (0.47) CXCR3EPHX2CYP2D6SMN1; SMN2NPSR1
SCHEMBL3410345 0.89 CXCR3 (0.46) CXCR3EPHX2CYP2D6SMN1; SMN2NPSR1
SCHEMBL3406473 0.88 CXCR3 (0.47) CXCR3EPHX2CYP2D6SMN1; SMN2NPSR1
SCHEMBL3412958 0.87 SMN1; SMN2 (0.46) CXCR3EPHX2CYP2D6SMN1; SMN2NPSR1
SCHEMBL3415543 0.86 CXCR3 (0.43) CXCR3EPHX2CYP2D6SMN1; SMN2KMT2A
SCHEMBL3412407 0.86 JAK2 (0.47) EPHX2SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL4109188 0.86 CXCR3 (0.44) CXCR3EPHX2CYP2D6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US claimed
EP-2262789-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-12-22 EP claimed
WO-2009109477-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO claimed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US claimed
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
EP-2262789-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-12-22 EP disclosed
WO-2009109477-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227570-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2A CXCR3 1841/4885EPHX2 2067/4885CYP2D6 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.